摘要
目的:探讨喹硫平治疗精神分裂症的临床疗效。方法:61例精神分裂症患者随机分成两组,分别予以喹硫平和氯丙嗪治疗,疗程8周。以阳性和阴性症状量表(PANSS)[1]评定疗效及治疗中出现的症状量表(TESS)[1]评定不良反应。结果:两组疗效无显著性差异(P>0.05),喹硫平组不良反应明显少于氯丙嗪组,依从性更高。结论:喹硫平与氯丙嗪对精神分裂症患者都有较好疗效,但奎硫平对减轻患者不良反应明显优于氯丙嗪。
Objective:To study the influence of quetiapine on chnical efficacy. Methods:Sixty -one patients with schizophre- nia were diveded into two groups randomly. They were treated with quetiapine and chlorpromazine respectively for 8 weeks. The effica- cy were evaluated with positive and negative syndrome scale (PANSS) and adverse effects were evaluated with treament emergent symptoms scale (TESS). Results: There was no significant difference in clinical efficacy between the two groups. Patients in quetiap- ine group less than chlorpromazine group adverse effects. The compliance of quetiapine was significantly better than that of chlorproma- zinc. Conclusions: Quetiapine have similar clinical efficacy as chlorpromazine in the treatment of schizophrenia, with more improve- ment to reduce side effects.
出处
《中国民康医学》
2012年第21期2597-2598,共2页
Medical Journal of Chinese People’s Health
关键词
喹硫平
氯丙嗪
精神分裂症
quetiapine
chlorpromazine
schizophrenia